PBYI logo

PBYI
Puma Biotechnology Inc

6,847
Mkt Cap
$381.18M
Volume
167,977.00
52W High
$7.90
52W Low
$2.85
PE Ratio
12.26
PBYI Fundamentals
Price
$7.49
Prev Close
$7.51
Open
$7.52
50D MA
$6.81
Beta
0.90
Avg. Volume
274,543.00
EPS (Annual)
$0.6142
P/B
2.90
Rev/Employee
$1.28M
$230.31
Loading...
Loading...
News
all
press releases
Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday
Puma Biotechnology (NASDAQ:PBYI) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-puma-biotechnology-inc-stock...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200-Day Moving Average - Should You Sell?
Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200 Day Moving Average - Should You Sell...
MarketBeat·4d ago
News Placeholder
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter...
Business Wire·9d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200 Day Moving Average - Should You Sell?
Puma Biotechnology (NASDAQ:PBYI) Share Price Passes Above 200-Day Moving Average - Here's What Happened...
MarketBeat·12d ago
News Placeholder
Puma Biotechnology, Inc. $PBYI Shares Acquired by Ritholtz Wealth Management
Ritholtz Wealth Management raised its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 47.4% during the fourth quarter, according to its most recent filing with the...
MarketBeat·21d ago
News Placeholder
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·24d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200 Day Moving Average - What's Next?
Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above Two Hundred Day Moving Average - What's Next...
MarketBeat·25d ago
News Placeholder
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Pumas Board of Directors approved the grant of inducement...
Business Wire·1mo ago
News Placeholder
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·1mo ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving Average - Should You Sell?
Puma Biotechnology (NASDAQ:PBYI) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...
MarketBeat·1mo ago
<
1
2
...
>

Latest PBYI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.